Concord Biotech (NSE:CONCORDBIO) Total Current Assets : ₹9,347 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Concord Biotech's total current assets for the quarter that ended in Sep. 2024 was ₹9,347 Mil.

Concord Biotech Total Current Assets Historical Data

The historical data trend for Concord Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech Total Current Assets Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Total Current Assets

5,385.83

6,071.47

6,326.66

7,277.00

8,962.31

Concord Biotech Quarterly Data
	Mar20	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial							7,556.47	-	8,962.31	-	9,346.52

Concord Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Concord Biotech's Total Current Assets for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2855.328	+	3684.928	+	2079.538	+	342.517
	=	8,962

Concord Biotech's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3182.936	+	3444.457	+	2504.245	+	214.886
	=	9,347

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Concord Biotech (NSE:CONCORDBIO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Concord Biotech's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3182.936	-	1739.656	+	0.75 * 3444.457	+	0.5 * 2504.245
=	5,279

Concord Biotech Total Current Assets Related Terms

Thank you for viewing the detailed overview of Concord Biotech's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (NSE:CONCORDBIO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

543960:India

Address

Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines